Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shexiang Baoxin Pill for Coronary Microvascular Dysfunction
NCT04984954Phase 4Unknown
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Shexiang Baoxin Pill in Coronary Microvascular Dysfunction (CMD) (2 arms). Primary endpoint: Heart Rate Recovery at 8 weeks. Status: unknown.
02
Drugs
Shexiang Baoxin Pill
03
Conditions
Coronary Microvascular Dysfunction (CMD)
Beyond the preview
Go deeper on NCT04984954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984954.